Abstract
Introduction
Causes of treatment failure in acute lymphoblastic leukemia (ALL) are still poorly understood. Microarray technology gives new possibilities for the analysis of the biology of leukemias. We hypothesize that drug sensitivity in pediatric ALL is driven by specific molecular mechanisms that correlate with gene expression profiles assessed by microarray analysis.
Objective
The aim of the study was to determine the ex vivo resistance profiles of 20 antileukemic drugs and gene expression profiles, with relation to response to initial therapy.
Patients and methods
Lymphoblasts were analyzed after bone marrow biopsy was obtained from 56 patients. The profile of in vitro resistance to drugs was determined in the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazoliumbromide (MTT) cytotoxicity assay. High-quality total RNA was prepared and hybridized to oligonucleotide arrays HG-U133A 2.0 Chip (Affymetrix). The expression of selected genes was tested by qualitative reverse transcription polymerase chain reaction (qRT-PCR).
Results and conclusions
The exposure of leukemic blasts to drugs initiates a complex cellular response, which reflects global changes in gene expression. Changes in the expression of several genes are highly correlated with drug resistance.
Similar content being viewed by others
References
Arceci RJ (1993) Clinical significance of P-glycoprotein in multidrug resistance malignancies. Blood 81:2215–2222
Bachman KE, Argani P, Samuels Y et al (2004) The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther 3:772–775
Bhojwani D, Kang H, Menezes RX et al (2008) Gene expression signatures predictive of early response and outcome in high-risk childhood acute lymphoblastic leukemia: A Children’s Oncology Group Study. J Clin Oncol 26:4376–4384
Blohm DH, Guiseppi-Elie A (2001) New developments in microarray technology. Curr Opin Biotechnol 12:41–47
Brown JR, Auger KR (2011) Phylogenomics of phosphoinositide lipid kinases: perspectives on the evolution of second messenger signaling and drug discovery. BMC Evol Biol 11:4
Cheok MH, Yang W, Pui CH et al (2003) Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells. Nat Genet 34:85–90
den Boer ML, Pieters R, Kazemier KM et al (1998) Relationship between major vault protein/lung resistance protein, multidrug resistance-associated protein, P-glycoprotein expression, and drug resistance in childhood leukemia. Blood 91:2092–2098
den Boer ML, Harms DO, Pieters R et al (2003) Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia. J Clin Oncol 21:3262–3268
Evans WE, Relling MV (2004) Moving towards individualized medicine with pharmacogenomics. Nature 429:464–468
Ferrando AA, Neuberg DS, Staunton J et al (2002) Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell 1:75–87
Garza-González E, Bosques-Padilla FJ, Pérez-Pérez GI et al (2004) Association of gastric cancer, HLA-DQA1, and infection with Helicobacter pylori CagA+ and VacA+ in a Mexican population. J Gastroenterol 39:1138–1142
Györffy B, Surowiak P, Kiesslich O et al (2006) Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer 118:1699–1712
Hoelzer D, Gökbuget N, Ottmann O et al (2002) Acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 162–192
Hofmann WK, de Vos S, Elashoff D et al (2002) Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study. Lancet 359:481–486
Holleman A, Cheok MH, den Boer ML et al (2004) Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med 351:533–542
Holleman A, den Boer ML, de Menezes RX et al (2006) The expression of 70 apoptosis genes in relation to lineage, genetic subtype, cellular drug resistance, and outcome in childhood acute lymphoblastic leukemia. Blood 107:769–776
Ikenoue T, Kanai F, Hikiba Y et al (2005) Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res 65:4562–4567
Jarzab B, Gubała E, Lange D (2005) DNA microarrays and papillary thyroid carcinoma gene expression profile. Endokrynol Pol 56:293–301
Jeha S, Pui CH (2009) Risk-adapted treatment of pediatric acute lymphoblastic leukemia. Hematol Oncol Clin North Am 23:973–990
Lugthart S, Cheok MH, den Boer ML et al (2005) Identification of genes associated with chemotherapy crossresistance and treatment response in childhood acute lymphoblastic leukemia. Cancer Cell 7:375–386
McLennan AG (2006) The Nudix hydrolase superfamily. Cell Mol Life Sci 63:123–143
Mildvan AS, Xia Z, Azurmendi HF et al (2005) Structures and mechanisms of Nudix hydrolases. Arch Biochem Biophys 433:129–143
Möricke A, Reiter A, Zimmermann M et al (2008) Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood 111:4477–4489
Möricke A, Zimmermann M, Reiter A et al (2010) Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia 24:265–284
Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29:e45
Planelles D, Nagore E, Moret A et al (2006) HLA class II polymorphisms in Spanish melanoma patients: homozygosity for HLA-DQA1 locus can be a potential melanoma risk factor. Br J Dermatol 154:261–266
Pui CH (2009) Toward a total cure for acute lymphoblastic leukemia. J Clin Oncol 27:5121–5123
Pui CH, Campana D, Pei D et al (2009) Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med 360:2730–2741
Riemersma SA, Jordanova ES, Schop RF et al (2000) Extensive genetic alterations of the HLA region, including homozygous deletions of HLA class II genes in B-cell lymphomas arising in immune-privileged sites. Blood 96:3569–3577
Samuels Y, Ericson K (2006) Oncogenic PI3K and its role in cancer. Curr Opin Oncol 18:77–82
Samuels Y, Wang Z, Bardelli A et al (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304:554
Schotte D, Pieters R, Den Boer ML (2011a) MicroRNAs in acute leukemia: from biological players to clinical contributors. Leukemia (in press). doi:10.1038/leu.2011.151
Schotte D, De Menezes RX, Moqadam FA et al (2011b) MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia. Haematologica 96:703–711
Shah AA, Meese E, Blin N (2010) Profiling of regulatory microRNA transcriptomes in various biological processes: a review. J Appl Genet 51:501–507
Staal FJ, de Ridder D, Szczepanski T et al (2010) Genome-wide expression analysis of paired diagnosis-relapse samples in ALL indicates involvement of pathways related to DNA replication, cell cycle and DNA repair, independent of immune phenotype. Leukemia 24:491–499
Styczyński J, Wysocki M (2004) Is the in vitro drug resistance profile the strongest prognostic factor in childhood acute lymphoblastic leukemia? J Clin Oncol 22:963–964
Styczynski J, Pieters R, Huismans DR et al (2000) In vitro drug resistance profiles of adult versus childhood acute lymphoblastic leukaemia. Br J Haematol 110:813–818
Styczynski J, Wysocki M, Debski R et al (2002) Ex vivo drug resistance profile in childhood acute myelogenous leukemia: no drug is more effective in comparison to acute lymphoblastic leukemia. Leuk Lymphoma 43:1843–1848
Styczynski J, Wysocki M, Dluzniewska A et al (2008) Prognostic impact of combined fludarabine, treosulfan and mitoxantrone resistance profile in childhood acute myeloid leukemia. Anticancer Res 28:1927–1931
Szczepanek J, Styczyński J, Haus O et al (2007) Gene expression profiles in acute lymphoblastic leukemia in children and adults. Postepy Hig Med Dosw (Online) 61:519–533
Thomas H, Coley HM (2003) Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 10:159–165
van den Heuvel-Eibrink MM, Sonneveld P, Pieters R (2000) The prognostic significance of membrane transport-associated multidrug resistance (MDR) proteins in leukemia. Int J Clin Pharmacol Ther 38:94–110
Vigorito E, Billadeu DD, Savoy D et al (2003) RhoG regulates gene expression and the actin cytoskeleton in lymphocytes. Oncogene 22:330–342
Vilar E, Mukherjee B, Kuick R et al (2009) Gene expression patterns in mismatch repair-deficient colorectal cancers highlight the potential therapeutic role of inhibitors of the phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathway. Clin Cancer Res 15:2829–2839
Willenbrock H, Juncker AS, Schmiegelow K et al (2004) Prediction of immunophenotype, treatment response, and relapse in childhood acute lymphoblastic leukemia using DNA microarrays. Leukemia 18:1270–1277
Yeoh EJ, Ross ME, Shurtleff SA et al (2002) Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 1:133–143
Zaza G, Cheok M, Yang W et al (2005) Gene expression and thioguanine nucleotide disposition in acute lymphoblastic leukemia after in vivo mercaptopurine treatment. Blood 106:1778–1785
Acknowledgments
This study was supported by Grant MNiSW No. N407 078 32/2964 and Grant UMK 10/2009.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Szczepanek, J., Jarzab, M., Oczko-Wojciechowska, M. et al. Gene expression signatures and ex vivo drug sensitivity profiles in children with acute lymphoblastic leukemia. J Appl Genetics 53, 83–91 (2012). https://doi.org/10.1007/s13353-011-0073-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13353-011-0073-x